Additional Relevant Details The FDA/US Government have agreed with Amarin to be bound by the court's earlier decision on August 7, 2015 that stated Amarin may "engage in truthful and non-misleading speech promoting the off-label use of Vascepa".  Vescepa is currently in a REDUCE-IT trial testing whether it will significantly reduce cardiovascular risk with statin treatment compared to statins alone in high-risk patients with elevated triglyceride levels.